Using CBD daily is associated with improved memory and reduced age-related cognitive decline, according to a study published in the journal Frontiers in Aging Neuroscience.
Most Parkinson’s disease (PD) patients who consume cannabis say that it mitigates their symptoms and improves their health-related quality of life.
Most patients with endometriosis say that cannabis is superior to pharmaceutical medications and possesses fewer side effects.
Marijuana consumers are more than three times more likely to regularly exercise than drink alcohol, and they're nearly five times more likely to work out routinely.
A majority of sports fans across multiple leagues—from the NFL to pro tennis and the NBA to NASCAR—say it’s acceptable for cannabis companies to sponsor teams.
An estimated seven percent of US adults ages 65 and older acknowledge having consumed cannabis within the past month, according to the journal JAMA Internal Medicine
Scientists identified 33 cannabis genome markers tied to cannabinoid production, paving the way for faster, targeted breeding and new strain innovation.
Patients with musculoskeletal pain experience symptomatic improvements and few side effects following the sustained use of medical cannabis, according to newly data published in the scientific journal Cureus . Investigators affiliated with the Rothman Orthopaedic Institute at Thomas Jefferson University in Philadelphia assessed the safety and efficacy of long-term cannabis use in a cohort of 129 patients suffering from musculoskeletal pain. Study participants were registered in Pennsylvania’s medical cannabis access program and were assessed for at least one year. Over three-quarters of study subjects reported using at least one type of cannabis product daily, with most (64 percent) choosing to use topical formulations. Consistent with prior studies, the majority (93 percent) of pain patients said that cannabis improved their primary symptoms. Cognitive and motor effects were minimal for most users, with 72 percent reporting “no impact” on their thinking, coordination, or motor functions. Some 40 percent of study participants acknowledged reducing their use of traditional analgesics, including opioids, following medical cannabis initiation – a finding that is also consistent with other studies. Source
Cannabinoids in medical marijuana can both increase the efficacy of chemotherapy drugs and also minimize the often uncomfortable side-effects of conventional cancer treatment, according to a new scientific review of available evidence. The 23-page paper, published online this month in the journal Pharmacology & Therapeutics, assesses a range of clinical and preclinical findings that “mainly relate to combination treatments for glioblastoma, hematological malignancies and breast cancer, but also for other cancer types. To summarize, the data available to date raise the prospect that cannabinoids may increase the efficacy of chemotherapeutic agents while reducing their side effects.” Overall, while the interactions between cannabinoids and chemotherapeutics “constitute a complex subject with many yet unknown variables,” the study says, there are “two important therapy-relevant aspects of the interaction between cannabinoids and chemotherapeutic agents that could potentially benefit cancer patients: firstly, the systemic potentiation of chemotherapeutics by cannabinoids, primarily leading to an extension of life by overcoming therapy resistance and secondly, the reduction of chemotherapy-induced side effects.” “In addition to this well-known antiemetic effect of cannabinoids,” the report adds, “an increasing number of preclinical studies discussed in this review have shown in recent years that cannabinoids can also have a positive effect on other side effects of chemotherapy, such as chemotherapy-induced peripheral neuropathy (CIPN), nephrotoxicity, cardiotoxicity, cystitis and mucositis.” While the report deals in less depth with other cancer-related symptoms, it notes that cannabinoids are also administered to relieve cancer-related chronic pain. Source
Nearly half of pediatric patients prescribed CBD in the form of Epidiolex achieve a 25 percent reduction in seizures, according to clinical trial data published in the journal Epilepsy & Behavior . Investigators affiliated with Tulane University’s School of Medicine assessed the adjunctive use of Epidiolex in 208 patients with treatment-resistant childhood epilepsy. Researchers reported a significant decrease in seizure frequency across all diagnostic categories, with an overall median reduction in monthly seizures from 30 to eight. Forty-nine percent of patients experienced a greater than 25 percent reduction in seizure frequency following CBD treatment. Twenty-one percent of participants experienced a 51 to 75 percent reduction in seizures. “Our study demonstrates that cannabidiol offers significant benefits in reducing seizure frequency across a variety of epilepsy etiologies in pediatric patients with medically refractory epilepsy,” the study’s authors concluded. “While CBD’s efficacy in conditions like Lennox-Gastaut Syndrome and Dravet Syndrome is well-documented our findings underscore CBD’s broader potential in managing other types of DEEs [developmental and epileptic encephalopathies], focal/multifocal epilepsy, and primary generalized epilepsy.” Source
